LM™ LLLT (Photobiomodulation)

Light Modulation, written as LM™ LLLT (PBM), is Espansione's patented low-level light therapy and the primary therapeutic modality across its platform. It is a form of photobiomodulation: the use of non-ionising, monochromatic light to stimulate cellular activity without heat, ablation or any invasive step. Rather than treating a symptom, it acts on the biological drivers of disease, which is why it has found application across both the front and the back of the eye.

What "low-level light therapy" means

The "low-level" in LLLT refers to the fact that the light is delivered below the threshold at which it would heat or damage tissue. The energy is instead absorbed by the cell and converted into a biological signal. The light is monochromatic, meaning a single, defined wavelength, which is what allows the dose and the target to be controlled precisely. This is the feature that separates a regulated medical device from a consumer gadget, where wavelength and dose are typically uncontrolled.

A therapy with a long scientific lineage

Photobiomodulation as a field traces back to discoveries in the 1970s about light's effect on cellular metabolism, and it has since accumulated a substantial basic-science and clinical literature across many areas of medicine. Espansione's contribution is to engineer this principle into precise, regulated devices for the eye and to validate specific ocular indications in peer-reviewed trials. See the mechanism-of-action literature.

How it is delivered

LM™ LLLT (PBM) is delivered on the professional eye-light® platform, which also carries OPE™ IPL, and in simplified form on the home-use my-mask®. The patient relaxes under a warming mask while the light is applied; the treatment is painless, requires no anaesthesia and has no downtime.

Where the evidence supports it

LM™ LLLT (PBM) is recognised in the TFOS DEWS III Management and Therapy Report (TFOS DEWS III, 2025, American Journal of Ophthalmology) as beneficial across the tear film, the eyelids and the ocular surface, and it serves as the primary modality where the evidence supports it, with OPE™ IPL added as an adjunct for severe or recalcitrant meibomian gland dysfunction. To understand the biology, read how photobiomodulation works.

Not all solutions and indications are cleared in all countries and for all cohorts. Every piece of information ought to be considered as fact-based evidence deriving from publicly available literature, for the sole purpose of scientific exchange.